Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Black Diamond Therapeutics (BDTX) Income towards Parent Company (2018 - 2025)

Black Diamond Therapeutics' Income towards Parent Company history spans 6 years, with the latest figure at -$16.4 million for Q4 2025.

  • For Q4 2025, Income towards Parent Company rose 7.25% year-over-year to -$16.4 million; the TTM value through Dec 2025 reached $16.6 million, up 121.65%, while the annual FY2025 figure was $16.6 million, 121.65% up from the prior year.
  • Income towards Parent Company reached -$16.4 million in Q4 2025 per BDTX's latest filing, down from -$9.8 million in the prior quarter.
  • In the past five years, Income towards Parent Company ranged from a high of $55.1 million in Q1 2025 to a low of -$34.6 million in Q3 2021.
  • Average Income towards Parent Company over 3 years is -$14.4 million, with a median of -$17.7 million recorded in 2024.
  • Peak YoY movement for Income towards Parent Company: tumbled 143.6% in 2021, then soared 381.12% in 2025.
  • A 3-year view of Income towards Parent Company shows it stood at -$34.6 million in 2021, then soared by 48.8% to -$17.7 million in 2024, then grew by 7.25% to -$16.4 million in 2025.
  • Per Business Quant, the three most recent readings for BDTX's Income towards Parent Company are -$16.4 million (Q4 2025), -$9.8 million (Q3 2025), and -$12.3 million (Q2 2025).